BYSI Archives | BioTuesdays

Markets

HCW downgrades BeyondSpring to neutral from buy; removes PT

H.C. Wainwright downgraded BeyondSpring (NASDAQ:BYSI) to “neutral” from “buy” and removed its price target, citing a change to the company’s risk profile. The stock closed at $10.80 on April 1. On March 31, BeyondSpring...

April 5, 2021

Markets

WB starts BeyondSpring at outperform

William Blair launched coverage of BeyondSpring (NASDAQ:BYSI) with an “outperform” rating. The stock closed at $12.45 on Dec. 2. According to analyst Andy Hsieh, the Street is “undervaluing the clinical potential” of...

December 3, 2019

Developments

Journals publish mechanism of action data for BeyondSpring’s Plinabulin

Two peer-reviewed scientific journals, Chem and Cell Reports, published new data that sheds light on the mechanism of action of BeyondSpring’s (NASDAQ:BYSI) lead Phase 3 asset, Plinabulin, which is being developed in...

October 8, 2019

Developments

BeyondSpring presents novel NSCLC study design for plinabulin

At the recent European Society for Medical Oncology Congress, BeyondSpring Pharmaceuticals (NASDAQ:BYSI) presented its novel study design for DUBLIN-3, a global Phase 3 trial assessing plinabulin in non-small cell lung...

October 1, 2019

Developments

BeyondSpring to present superior product data in breast cancer neutropenia prevention

BeyondSpring’s (NASDAQ:BYSI) poster with findings from its Study 106 has been accepted for presentation at this year’s European Society for Medical Oncology Congress in Barcelona on Sept. 28. In Study 106, BeyondSpring...

September 23, 2019

Developments

BeyondSpring presents Phase 3 NSCLC study design at world conference on lung cancer

BeyondSpring (NASDAQ: BYSI) presented a poster of the design for its Phase 3 Study 103 at the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain on Sept. 9. Study 103 is a multi-center...

September 10, 2019

Developments

BeyondSpring’s Plinabulin demonstrates superior quality of life for prevention of neutropenia

BeyondSpring (NASDAQ: BYSI) plans to present positive data in an abstract titled, “Quality of Life (QoL) in Advanced NSCLC Patients Treated with Docetaxel and with Either Plinabulin or Pegfilgrastim for the Prevention...

August 23, 2019

Markets

Dawson James starts BeyondSpring at buy; PT $39

Dawson James Securities initiated coverage of BeyondSpring (NASDAQ:BYSI) with a “buy” rating and price target of $39. The stock closed at $16.21 on Aug. 15. “BeyondSpring’s [flagship molecule] Plinabulin is well...

August 16, 2019

Developments

BeyondSpring prices $35-million equity offering

BeyondSpring (NASDAQ:BYSI) priced a public offering of 2,058,825 ordinary shares at $17 apiece for expected gross proceeds of $35-million. The offering was led by Decheng Capital. The underwriter has a 30-day option to...

July 17, 2019

Developments

BeyondSpring presents bone pain relief abstract for Plinabulin at ISPOR

BeyondSpring’s (NASDAQ:BYSI) abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 2019 conference May 18-22 in New...

May 21, 2019

Tag - BYSI

HCW downgrades BeyondSpring to neutral from buy; removes PT

WB starts BeyondSpring at outperform

Journals publish mechanism of action data for BeyondSpring’s Plinabulin

BeyondSpring presents novel NSCLC study design for plinabulin

BeyondSpring to present superior product data in breast cancer neutropenia prevention

BeyondSpring presents Phase 3 NSCLC study design at world conference on lung cancer

BeyondSpring’s Plinabulin demonstrates superior quality of life for prevention of neutropenia

Dawson James starts BeyondSpring at buy; PT $39

BeyondSpring prices $35-million equity offering

BeyondSpring presents bone pain relief abstract for Plinabulin at ISPOR

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter